DC Chemicals Limited
China
Product Name: Vonoprazan hydrochloride
Price: ￥Inquiry/100mg ￥Inquiry/250mg ￥Inquiry/1g
Purity: 98.0%
Stocking Period: 10 Day
Contact: Tony Cao
Email: sales@dcchemicals.com

1957202-44-6

1957202-44-6 structure

Name: Vonoprazan hydrochloride
Chemical Name: Vonoprazan hydrochloride
CAS Number: 1957202-44-6
Molecular Formula: C₁₇H₁₇ClFN₃O₂S
Molecular Weight: 381.85
Catalog: Signaling Pathways Anti-infection Bacterial
Create Date: 2022-08-14 17:46:10
Modify Date: 2025-08-25 17:58:31
Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori[1][2][3].

Name	Vonoprazan hydrochloride

Description	Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori[1][2][3].
Related Catalog	Research Areas >> Endocrinology Research Areas >> Infection Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump Signaling Pathways >> Anti-infection >> Bacterial
Target	IC50: 19 nM (porcine gastric H+,K+-ATPase, at pH 6.5)[2]
In Vitro	Vonoprazan (0.1 nM-10 μM; 30 minutes) exhibits porcine gastric H+, K+-ATPase activity in a concentration-dependent manner[2]. Vonoprazan does not inhibit Na+,K+-ATPase activity, even at concentrations 500 times higher than their IC50 values against gastric H+,K+-ATPase activity[2].
In Vivo	Vonoprazan (1-4 mg/kg; p.o.) completely inhibits basal and 2-deoxy-D-glucose (200 mg/kg; s.c.)-stimulated gastric acid secretion at the 4 mg/kg dose in rats[2]. Animal Model: Male 7- or 8-week-old Sprague-Dawley rat[2] Dosage: 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg Administration: Oral administration Result: Inhibited basal gastric acid secretion in a dose-dependent manner.
References	[1]. Arikawa Y, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem, 2012, 55(9), 4446-4456. [2]. Hori Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther, 2010, 335(1), 231-238. [3]. Sugimoto M, et al. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Front Pharmacol. 2019 Jan 15;9:1560.

Molecular Formula	C₁₇H₁₇ClFN₃O₂S
Molecular Weight	381.85

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1957202-44-6	1406-14-0
6138-79-0	127228-87-9
1406-02-6	929-73-7
143851-98-3	1334385-87-3
56-99-5	75752-15-7
1111020-26-8	1110980-47-6
1111020-82-6	1111003-37-2
1243007-59-1	1242860-01-0
1223785-19-0	1306604-61-4
1122093-35-9	676363-06-7